Description: Rabbit polyclonal antibody to TRK B Immunogen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human TRK B. The exact sequence is proprietary. Purification: The antibody was purified by immunogen affinity chromatography. Clonality: Polyclonal Form: Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Dilution: WB (1/500 - 1/1000), IH (1/50 - 1/100), IF/IC (1/50 - 1/200) Gene Symbol: NTRK2 Alternative Names: TRKB; BDNF/NT-3 growth factors receptor; GP145-TrkB; Trk-B; Neurotrophic tyrosine kinase receptor type 2; TrkB tyrosine kinase; Tropomyosin-related kinase BEntrez Gene (Human): 4915Entrez Gene (Mouse) : 18212Entrez Gene (Rat) : 25054SwissProt (Human): Q16620SwissProt (Mouse) : P15209SwissProt (Rat) : Q63604Storage/Stability : Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.
-
Western blot analysis of TRK B expression in rat heart (A), mouse kidney (B) whole cell lysates.
-
Immunohistochemical analysis of TRK B staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
-
Immunofluorescent analysis of TRK B staining in HL60 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Muskelin Coordinates PrPC Lysosome versus Exosome Targeting and Impacts Prion Disease Progression